Critical Comparison: TransMedics Group (NASDAQ:TMDX) vs. Bone Biologics (NASDAQ:BBLG)

Bone Biologics (NASDAQ:BBLG) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Volatility & Risk

Bone Biologics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500.

Profitability

This table compares Bone Biologics and TransMedics Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-50.47%	-47.40%
TransMedics Group	22.69%	15.88%	5.95%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Bone Biologics and TransMedics Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1	0	0	0	1.00
TransMedics Group	1	6	6	0	2.38

TransMedics Group has a consensus target price of $124.18, indicating a potential upside of 48.03%. Given TransMedics Group’s stronger consensus rating and higher possible upside, analysts clearly believe TransMedics Group is more favorable than Bone Biologics.

Earnings & Valuation

This table compares Bone Biologics and TransMedics Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11 million	($2.27)	-0.41
TransMedics Group	$605.49 million	4.79	$190.29 million	$3.89	21.57

TransMedics Group has higher revenue and earnings than Bone Biologics. Bone Biologics is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 5.6% of Bone Biologics shares are owned by insiders. Comparatively, 6.9% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

TransMedics Group beats Bone Biologics on 13 of the 13 factors compared between the two stocks.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

About TransMedics Group

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.